<p><em>- 添加 dordaviprone 強化了 Jazz 的晚期腫瘤學管線，並重申了對解決具有重大未滿足需求的罕見疾病的承諾 -</em></p>
<p>, /PRNewswire/ -- Jazz Pharmaceuticals plc (納斯達克: JAZZ)（&#34;Jazz&#34; 或 &#34;公司&#34;）今天宣佈成功完成對 Chimerix, Inc.（&#34;Chimerix&#34;）的收購，交易金額約為 9.35 億美元現金。Chimerix 現在是 Jazz 的全資子公司。</p>
<p>&#34;將 Chimerix 納入 Jazz 為我們的腫瘤學產品組合增添了一種新型藥物，並推動我們解決未滿足患者需求的努力，&#34; Jazz 的董事長兼首席執行官 Bruce Cozadd 説。&#34;Dordaviprone 有潛力成為 FDA 首個也是唯一批准用於 H3 K27M 突變瀰漫性膠質瘤患者的治療，如果獲得批准，將提供一個有前景的短期商業機會。我們很高興歡迎 Chimerix 的優秀團隊，共同推進 dordaviprone，利用我們的開發和商業能力，儘快將這一療法提供給患者，預計在今年下半年。&#34;</p>
<p>dordaviprone 的加入是一種新型的首創小分子治療，正在開發用於 H3 K27M 突變瀰漫性膠質瘤，進一步豐富併為 Jazz 的腫瘤學管線增加了短期商業機會。dordaviprone 目前正在接受美國食品藥品監督管理局（FDA）的優先審查，處方藥用户收費法案（PDUFA）行動日期定於 2025 年 8 月 18 日。如果在美國獲得批准，該療法可能有資格獲得罕見兒科疾病優先審查憑證（PRV）。dordaviprone 還在進行中的 III 期 ACTION 試驗中進行研究，以評估其在新診斷的非複發性 H3 K27M 突變瀰漫性膠質瘤患者放療後的使用，可能將其應用擴展到一線治療。</p>
<p><strong>交易詳情</strong> Jazz 對 Chimerix 所有流通普通股（每股面值 0.001 美元）的要約於 2025 年 4 月 17 日東部時間晚上 11:59 之後的一分鐘到期。Jazz 已接受有效投標且未有效撤回的所有股票，現金支付每股 8.55 美元，不計利息，並可能因適用的預扣税而減少。在接受投標股票後，Jazz 通過與 Chimerix 合併的方式完成了對 Chimerix 的收購，合併方為 Pinetree Acquisition Sub, Inc.，一家特拉華州公司，是 Jazz 的間接全資子公司（&#34;購買方&#34;）。合併後，購買方的獨立存在終止，Chimerix 繼續作為存續公司，併成為 Jazz 的間接全資子公司。有關要約的更多詳細信息，請參閲 Jazz 今天向 SEC 提交的 8-K 表格。</p>
<p><strong>關於 Dordaviprone</strong> Dordaviprone (ONC201) 是一種新型的首創小分子 imipridone，選擇性靶向線粒體蛋白酶 ClpP 和多巴胺受體 D2 (DRD2)。Dordaviprone 的獨特作用機制包括對關鍵表觀遺傳修飾的改變，如 H3 K27me3 喪失的逆轉，這是 H3 K27M 突變膠質瘤的標誌。</p>
<p><strong>關於 Jazz Pharmaceuticals</strong> Jazz Pharmaceuticals plc (NASDAQ: JAZZ) 是一家全球生物製藥公司，其宗旨是創新以改變患者及其家庭的生活。我們致力於為患有嚴重疾病的人開發改變生活的藥物——通常是治療選擇有限或沒有治療選擇的疾病。我們擁有多樣化的上市藥物組合，包括領先的睡眠障礙和癲癇治療藥物，以及不斷增長的癌症治療組合。我們以患者為中心、以科學為驅動的方法推動我們在腫瘤學和神經科學領域的創新治療的研究和開發進展。Jazz 總部位於愛爾蘭都柏林，在多個國家設有研究和開發實驗室、製造設施及員工，致力於為全球患者服務。有關更多信息，請訪問 www.jazzpharmaceuticals.com。</p>
<p><strong>關於前瞻性聲明的警示</strong> 本通訊包含涉及 Jazz 和 Chimerix 未來事件及未來表現的前瞻性聲明，這些聲明涉及風險和不確定性，包括關於收購的潛在好處的聲明，包括 dordaviprone 有可能成為 FDA 批准的首個也是唯一的 H3 K27M 突變瀰漫性膠質瘤患者治療藥物的潛力，以及其可能提供的有希望的近期商業機會；如果獲得批准，dordaviprone 在美國的近期商業推出潛力；正在進行的第三階段 ACTION 試驗確認 dordaviprone 在複發性 H3 K27M 突變瀰漫性膠質瘤中的臨牀益處並擴展其在一線患者中的使用潛力；dordaviprone 可能有資格獲得罕見兒科疾病 PRV；以及其他非歷史事實的聲明。實際結果可能與這些前瞻性聲明中預期的結果有實質性差異。可能導致這些前瞻性聲明不準確的風險包括但不限於：預測監管批准或行動的時間或結果的困難的不確定性；與實現收購預期好處相關的風險，包括收購預期好處未能實現或未能在預期時間內實現的可能性，以及 Jazz 和 Chimerix 未能成功整合或整合可能比預期更困難、耗時或成本更高；交易對員工、客户、供應商、其他商業夥伴或政府實體關係的影響；顯著的交易成本；未知或無法估計的負債；與收購相關的訴訟和/或監管行動的風險；有效推出和商業化產品及產品候選者（如 dordaviprone，如果獲得批准）；成功完成與 dordaviprone 相關的開發和監管活動；獲得和維持 Jazz 產品的足夠覆蓋和報銷；耗時且不確定的監管批准過程，包括 Chimerix 針對 dordaviprone 尋求加速批准用於治療 H3 K27M 突變瀰漫性膠質瘤的成人和兒童患者的 NDA 可能未能及時獲得 FDA 批准或根本未獲批准的風險，以及 Chimerix 和/或 Jazz 可能未能在 dordaviprone 潛在批准時獲得罕見兒科疾病 PRV；藥品開發的高成本和耗時以及臨牀成功的不確定性，包括與成功啓動或完成臨牀試驗和評估患者相關的失敗或延遲風險，包括當前和計劃中的 dordaviprone 未來臨牀試驗；全球經濟、金融和醫療系統的干擾，以及當前和未來可能對 Jazz 的業務運營和財務結果產生負面影響的潛在影響；以及影響 Jazz 的其他風險和不確定性，包括在其向美國證券交易委員會的文件和報告中不時描述的 “風險因素” 標題下的風險，包括 Jazz 截至 2024 年 12 月 31 日的財政年度的 10-K 年度報告及未來的文件和報告。公司目前未意識到的其他風險和不確定性也可能影響其前瞻性聲明，並可能導致實際結果和事件時間與預期有實質性差異。本新聞稿中所作的前瞻性聲明僅在本日期作出，即使公司隨後在其網站或其他地方提供這些聲明。公司沒有義務更新或補充任何前瞻性聲明，以反映實際結果、新信息、未來事件、預期變化或在前瞻性聲明作出日期之後存在的其他情況。</p>
<p><strong>聯繫方式</strong></p>
<p><strong>投資者：</strong> Jeff Macdonald</p>
<p>投資者關係執行董事</p>
<p>Jazz Pharmaceuticals plc</p>
<p>[email protected]</p>
<p>愛爾蘭 +353 1 634 3211</p>
<p>美國 +1 650 496 2717</p>
<p><strong>媒體：</strong></p>
<p>Kristin Bhavnani</p>
<p>全球企業傳播負責人</p>
<p>Jazz Pharmaceuticals plc</p>
<p>[email protected]</p>
<p>愛爾蘭 +353 1 637 2141</p>
<p>美國 +1 215 867 4948</p>
<p>來源 Jazz Pharmaceuticals plc</p>
<p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUwNDIxJk5ld3NJdGVtSWQ9U0Y2ODMwNCZUcmFuc21pc3Npb25fSWQ9MjAyNTA0MjExNjA1UFJfTkVXU19VU1BSX19fX19TRjY4MzA0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUwNDIxJk5ld3NJdGVtSWQ9U0Y2ODMwNCZUcmFuc21pc3Npb25fSWQ9MjAyNTA0MjExNjA1UFJfTkVXU19VU1BSX19fX19TRjY4MzA0"/></p>

爵士制藥

CMRX

<p>爵士製藥已完成對 Chimerix 的收購，交易金額約為 9.35 億美元現金。這項收購增強了爵士的腫瘤學管線，特別是 dordaviprone，這是一種潛在的首個獲得 FDA 批准的 H3 K27M 突變瀰漫性膠質瘤治療藥物。該藥物正在接受 FDA 的優先審查，預計將在 2025 年 8 月 18 日之前作出決定。此次合併使 Chimerix 成為爵士的全資子公司，爵士旨在利用其能力盡快將該療法提供給患者。爵士致力於開發針對嚴重疾病的創新治療方案</p>

<p><em>- Addition of dordaviprone strengthens Jazz's late-stage oncology pipeline and reinforces commitment to addressing rare diseases with significant unmet need -</em></p>
<div class="lb-trans"><p><em>- 添加 dordaviprone 強化了 Jazz 的晚期腫瘤學管線，並重申了對解決具有重大未滿足需求的罕見疾病的承諾 -</em></p>
</div><p>, /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) (&#34;Jazz&#34; or the &#34;Company&#34;) today announced the successful completion of its acquisition of Chimerix, Inc. (&#34;Chimerix&#34;) for approximately $935 million in cash. Chimerix is now a wholly owned subsidiary of Jazz.</p>
<div class="lb-trans"><p>, /PRNewswire/ -- Jazz Pharmaceuticals plc (納斯達克: JAZZ)（&#34;Jazz&#34; 或 &#34;公司&#34;）今天宣佈成功完成對 Chimerix, Inc.（&#34;Chimerix&#34;）的收購，交易金額約為 9.35 億美元現金。Chimerix 現在是 Jazz 的全資子公司。</p>
</div><p>&#34;Bringing Chimerix into Jazz adds a novel medicine to our oncology portfolio and advances our efforts to address unmet patient needs,&#34; said Bruce Cozadd, chairman and chief executive officer of Jazz. &#34;Dordaviprone has the potential to become the first and only FDA-approved therapy for patients with H3 K27M-mutant diffuse glioma and offers a promising near-term commercial opportunity, if approved. We are excited to welcome Chimerix's talented team as we collectively continue to advance dordaviprone, leveraging our development and commercial capabilities to deliver this therapy to patients as soon as the second half of this year.&#34;</p>
<div class="lb-trans"><p>&#34;將 Chimerix 納入 Jazz 為我們的腫瘤學產品組合增添了一種新型藥物，並推動我們解決未滿足患者需求的努力，&#34; Jazz 的董事長兼首席執行官 Bruce Cozadd 説。&#34;Dordaviprone 有潛力成為 FDA 首個也是唯一批准用於 H3 K27M 突變瀰漫性膠質瘤患者的治療，如果獲得批准，將提供一個有前景的短期商業機會。我們很高興歡迎 Chimerix 的優秀團隊，共同推進 dordaviprone，利用我們的開發和商業能力，儘快將這一療法提供給患者，預計在今年下半年。&#34;</p>
</div><p>The addition of dordaviprone, a novel first-in-class small molecule treatment in development for H3 K27M-mutant diffuse glioma, further diversifies and adds near-term commercial opportunity to Jazz's oncology pipeline. Dordaviprone is currently under Priority Review by the U.S. Food and Drug Administration (FDA), with a Prescription Drug User Fee Act (PDUFA) action date set for August 18, 2025. If approved in the U.S., the therapy may be eligible for a Rare Pediatric Disease Priority Review Voucher (PRV). Dordaviprone is also being studied in the ongoing Phase 3 ACTION trial to evaluate its use in newly diagnosed, non-recurrent H3 K27M-mutant diffuse glioma patients following radiation treatment, potentially extending its use into the first-line setting.</p>
<div class="lb-trans"><p>dordaviprone 的加入是一種新型的首創小分子治療，正在開發用於 H3 K27M 突變瀰漫性膠質瘤，進一步豐富併為 Jazz 的腫瘤學管線增加了短期商業機會。dordaviprone 目前正在接受美國食品藥品監督管理局（FDA）的優先審查，處方藥用户收費法案（PDUFA）行動日期定於 2025 年 8 月 18 日。如果在美國獲得批准，該療法可能有資格獲得罕見兒科疾病優先審查憑證（PRV）。dordaviprone 還在進行中的 III 期 ACTION 試驗中進行研究，以評估其在新診斷的非複發性 H3 K27M 突變瀰漫性膠質瘤患者放療後的使用，可能將其應用擴展到一線治療。</p>
</div><p><strong>Transaction Details</strong> Jazz's tender offer for all outstanding shares of common stock, par value $0.001 per share, of Chimerix expired at one minute after 11:59 p.m., Eastern Time, on April 17, 2025. Jazz has accepted for payment of $8.55 per share, in cash, without interest and subject to reduction for any applicable withholding taxes, all shares that were validly tendered and not validly withdrawn. Following its acceptance of the tendered shares, Jazz completed the acquisition of Chimerix through the merger of Pinetree Acquisition Sub, Inc., a Delaware corporation, an indirect wholly owned subsidiary of Jazz (&#34;Purchaser&#34;) with and into Chimerix (the &#34;Merger&#34;). As a result of the Merger, the separate existence of Purchaser ceased, and Chimerix continued as the surviving corporation and an indirect wholly owned subsidiary of Jazz. Additional details regarding the tender can be found in a form 8-K filed by Jazz today with the SEC.</p>
<div class="lb-trans"><p><strong>交易詳情</strong> Jazz 對 Chimerix 所有流通普通股（每股面值 0.001 美元）的要約於 2025 年 4 月 17 日東部時間晚上 11:59 之後的一分鐘到期。Jazz 已接受有效投標且未有效撤回的所有股票，現金支付每股 8.55 美元，不計利息，並可能因適用的預扣税而減少。在接受投標股票後，Jazz 通過與 Chimerix 合併的方式完成了對 Chimerix 的收購，合併方為 Pinetree Acquisition Sub, Inc.，一家特拉華州公司，是 Jazz 的間接全資子公司（&#34;購買方&#34;）。合併後，購買方的獨立存在終止，Chimerix 繼續作為存續公司，併成為 Jazz 的間接全資子公司。有關要約的更多詳細信息，請參閲 Jazz 今天向 SEC 提交的 8-K 表格。</p>
</div><p><strong>About Dordaviprone</strong> Dordaviprone (ONC201) is a novel first-in-class small molecule imipridone that selectively targets the mitochondrial protease ClpP and dopamine receptor D2 (DRD2). Dordaviprone's unique mechanism of action includes alterations of key epigenetic modifications such as reversal of H3 K27me3-loss, which is the hallmark of H3 K27M-mutant gliomas.</p>
<div class="lb-trans"><p><strong>關於 Dordaviprone</strong> Dordaviprone (ONC201) 是一種新型的首創小分子 imipridone，選擇性靶向線粒體蛋白酶 ClpP 和多巴胺受體 D2 (DRD2)。Dordaviprone 的獨特作用機制包括對關鍵表觀遺傳修飾的改變，如 H3 K27me3 喪失的逆轉，這是 H3 K27M 突變膠質瘤的標誌。</p>
</div><p><strong>About Jazz Pharmaceuticals</strong> Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is a global biopharmaceutical company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with serious diseases — often with limited or no therapeutic options. We have a diverse portfolio of marketed medicines, including leading therapies for sleep disorders and epilepsy, and a growing portfolio of cancer treatments. Our patient-focused and science-driven approach powers pioneering research and development advancements across our robust pipeline of innovative therapeutics in oncology and neuroscience. Jazz is headquartered in Dublin, Ireland with research and development laboratories, manufacturing facilities and employees in multiple countries committed to serving patients worldwide. Please visit www.jazzpharmaceuticals.com for more information.</p>
<div class="lb-trans"><p><strong>關於 Jazz Pharmaceuticals</strong> Jazz Pharmaceuticals plc (NASDAQ: JAZZ) 是一家全球生物製藥公司，其宗旨是創新以改變患者及其家庭的生活。我們致力於為患有嚴重疾病的人開發改變生活的藥物——通常是治療選擇有限或沒有治療選擇的疾病。我們擁有多樣化的上市藥物組合，包括領先的睡眠障礙和癲癇治療藥物，以及不斷增長的癌症治療組合。我們以患者為中心、以科學為驅動的方法推動我們在腫瘤學和神經科學領域的創新治療的研究和開發進展。Jazz 總部位於愛爾蘭都柏林，在多個國家設有研究和開發實驗室、製造設施及員工，致力於為全球患者服務。有關更多信息，請訪問 www.jazzpharmaceuticals.com。</p>
</div><p><strong>Caution Concerning Forward-Looking Statements</strong> This communication contains forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Jazz and Chimerix, including statements regarding the prospective benefits of the acquisition, including benefits from dordaviprone's potential to become the first and only FDA-approved therapy for patients with H3 K27M-mutant diffuse glioma and its potential to offer a promising near-term commercial opportunity; the potential for a near-term commercial launch of dordaviprone in the U.S. if approved; the potential of the ongoing Phase 3 ACTION trial to confirm clinical benefit of dordaviprone in recurrent H3 K27M-mutant diffuse glioma and extend its use in first-line patients; dordaviprone potentially being eligible for a Rare Pediatric Disease PRV; and other statements that are not historical facts. Actual results could differ materially from those anticipated in these forward-looking statements. Risks that may cause these forward-looking statements to be inaccurate include, without limitation: uncertainties as to the difficulty of predicting the timing or outcome of regulatory approvals or actions, if any; risks related to the ability to realize the anticipated benefits of the acquisition, including the possibility that the expected benefits from the acquisition will not be realized or will not be realized within the expected time period and that Jazz and Chimerix will not be integrated successfully or that such integration may be more difficult, time-consuming or costly than expected; the effects of the transaction on relationships with employees, customers, suppliers, other business partners or governmental entities; significant transaction costs; unknown or inestimable liabilities; the risk of litigation and/or regulatory actions related to the acquisition; effectively launching and commercializing products and product candidates such as dordaviprone, if approved; the successful completion of development and regulatory activities with respect to dordaviprone; obtaining and maintaining adequate coverage and reimbursement for Jazz's products; the time-consuming and uncertain regulatory approval process, including the risk that Chimerix's NDA for dordaviprone seeking accelerated approval for treatment of H3 K27M-mutant diffuse glioma in adult and pediatric patients with progressive disease following prior therapy may not be approved by FDA in a timely manner or at all, and that Chimerix and/or Jazz may not receive a Rare Pediatric Disease PRV upon potential approval of dordaviprone; the costly and time-consuming pharmaceutical product development and the uncertainty of clinical success, including risks related to failure or delays in successfully initiating or completing clinical trials and assessing patients, including with respect to current and planned future clinical trials of dordaviprone; global economic, financial, and healthcare system disruptions and the current and potential future negative impacts to Jazz's business operations and financial results; and other risks and uncertainties affecting Jazz, including those described from time to time under the caption &#34;Risk Factors&#34; and elsewhere in its filings and reports with the U.S. Securities and Exchange Commission, including Jazz's Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and future filings and reports. Other risks and uncertainties of which the Company is not currently aware may also affect its forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated. The forward-looking statements made in this press release are made only as of the date hereof, even if they are subsequently made available by the Company on its website or otherwise. The Company undertakes no obligation to update or supplement any forward-looking statements to reflect actual results, new information, future events, changes in its expectations or other circumstances that exist after the date as of which the forward-looking statements were made.</p>
<div class="lb-trans"><p><strong>關於前瞻性聲明的警示</strong> 本通訊包含涉及 Jazz 和 Chimerix 未來事件及未來表現的前瞻性聲明，這些聲明涉及風險和不確定性，包括關於收購的潛在好處的聲明，包括 dordaviprone 有可能成為 FDA 批准的首個也是唯一的 H3 K27M 突變瀰漫性膠質瘤患者治療藥物的潛力，以及其可能提供的有希望的近期商業機會；如果獲得批准，dordaviprone 在美國的近期商業推出潛力；正在進行的第三階段 ACTION 試驗確認 dordaviprone 在複發性 H3 K27M 突變瀰漫性膠質瘤中的臨牀益處並擴展其在一線患者中的使用潛力；dordaviprone 可能有資格獲得罕見兒科疾病 PRV；以及其他非歷史事實的聲明。實際結果可能與這些前瞻性聲明中預期的結果有實質性差異。可能導致這些前瞻性聲明不準確的風險包括但不限於：預測監管批准或行動的時間或結果的困難的不確定性；與實現收購預期好處相關的風險，包括收購預期好處未能實現或未能在預期時間內實現的可能性，以及 Jazz 和 Chimerix 未能成功整合或整合可能比預期更困難、耗時或成本更高；交易對員工、客户、供應商、其他商業夥伴或政府實體關係的影響；顯著的交易成本；未知或無法估計的負債；與收購相關的訴訟和/或監管行動的風險；有效推出和商業化產品及產品候選者（如 dordaviprone，如果獲得批准）；成功完成與 dordaviprone 相關的開發和監管活動；獲得和維持 Jazz 產品的足夠覆蓋和報銷；耗時且不確定的監管批准過程，包括 Chimerix 針對 dordaviprone 尋求加速批准用於治療 H3 K27M 突變瀰漫性膠質瘤的成人和兒童患者的 NDA 可能未能及時獲得 FDA 批准或根本未獲批准的風險，以及 Chimerix 和/或 Jazz 可能未能在 dordaviprone 潛在批准時獲得罕見兒科疾病 PRV；藥品開發的高成本和耗時以及臨牀成功的不確定性，包括與成功啓動或完成臨牀試驗和評估患者相關的失敗或延遲風險，包括當前和計劃中的 dordaviprone 未來臨牀試驗；全球經濟、金融和醫療系統的干擾，以及當前和未來可能對 Jazz 的業務運營和財務結果產生負面影響的潛在影響；以及影響 Jazz 的其他風險和不確定性，包括在其向美國證券交易委員會的文件和報告中不時描述的 “風險因素” 標題下的風險，包括 Jazz 截至 2024 年 12 月 31 日的財政年度的 10-K 年度報告及未來的文件和報告。公司目前未意識到的其他風險和不確定性也可能影響其前瞻性聲明，並可能導致實際結果和事件時間與預期有實質性差異。本新聞稿中所作的前瞻性聲明僅在本日期作出，即使公司隨後在其網站或其他地方提供這些聲明。公司沒有義務更新或補充任何前瞻性聲明，以反映實際結果、新信息、未來事件、預期變化或在前瞻性聲明作出日期之後存在的其他情況。</p>
</div><p><strong>Contacts</strong></p>
<div class="lb-trans"><p><strong>聯繫方式</strong></p>
</div><p><strong>Investors:</strong> Jeff Macdonald</p>
<div class="lb-trans"><p><strong>投資者：</strong> Jeff Macdonald</p>
</div><p>Executive Director, Investor Relations</p>
<div class="lb-trans"><p>投資者關係執行董事</p>
</div><p>Jazz Pharmaceuticals plc</p>
<div class="lb-trans"><p>Jazz Pharmaceuticals plc</p>
</div><p>[email protected]</p>
<div class="lb-trans"><p>[email protected]</p>
</div><p>Ireland +353 1 634 3211</p>
<div class="lb-trans"><p>愛爾蘭 +353 1 634 3211</p>
</div><p>U.S. +1 650 496 2717</p>
<div class="lb-trans"><p>美國 +1 650 496 2717</p>
</div><p><strong>Media:</strong></p>
<div class="lb-trans"><p><strong>媒體：</strong></p>
</div><p>Kristin Bhavnani</p>
<div class="lb-trans"><p>Kristin Bhavnani</p>
</div><p>Head of Global Corporate Communications</p>
<div class="lb-trans"><p>全球企業傳播負責人</p>
</div><p>Jazz Pharmaceuticals plc</p>
<div class="lb-trans"><p>Jazz Pharmaceuticals plc</p>
</div><p>[email protected]</p>
<div class="lb-trans"><p>[email protected]</p>
</div><p>Ireland +353 1 637 2141</p>
<div class="lb-trans"><p>愛爾蘭 +353 1 637 2141</p>
</div><p>U.S. +1 215 867 4948</p>
<div class="lb-trans"><p>美國 +1 215 867 4948</p>
</div><p>SOURCE Jazz Pharmaceuticals plc</p>
<div class="lb-trans"><p>來源 Jazz Pharmaceuticals plc</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUwNDIxJk5ld3NJdGVtSWQ9U0Y2ODMwNCZUcmFuc21pc3Npb25fSWQ9MjAyNTA0MjExNjA1UFJfTkVXU19VU1BSX19fX19TRjY4MzA0" alt="" original-src="https://rt.prnewswire.com/rt.gif?NewsItemId=SF68304&amp;Transmission_Id=202504211605PR_NEWS_USPR_____SF68304&amp;DateId=20250421"/></p>

爵士製藥完成對 Chimerix 的收購